Suppr超能文献

趋化因子-趋化因子受体对的分配:胸腺活化调节趋化因子(TARC)和巨噬细胞炎性蛋白-1β(MIP-1β)不是人CC趋化因子受体8的配体。

The assignment of chemokine-chemokine receptor pairs: TARC and MIP-1 beta are not ligands for human CC-chemokine receptor 8.

作者信息

Garlisi C G, Xiao H, Tian F, Hedrick J A, Billah M M, Egan R W, Umland S P

机构信息

Allergy and Immunology, Schering-Plough Research Institute, Kenilworth 07033-0539, USA.

出版信息

Eur J Immunol. 1999 Oct;29(10):3210-5. doi: 10.1002/(SICI)1521-4141(199910)29:10<3210::AID-IMMU3210>3.0.CO;2-W.

Abstract

Identification of chemokine receptors and their associated ligands is crucial to the understanding of most immune reactions. Three human chemokines [I-309, thymus and activation-regulated chemokine (TARC) and macrophage inflammatory protein-1beta (MIP-1beta)] have been reported to be ligands for CC-chemokine receptor 8 (CCR8). In this report, we present evidence that TARC and MIP-1beta did not bind to or induce chemotaxis through CCR8 on a stable transfected cell line (1D-21) and did not bind to CCR8 on in vitro differentiated human CD4(+) Th(2) cell cultures. Also, I-309-dependent calcium mobilization in 1D-21 cells and in Th(2) cells was desensitized by I-309 but not by MIP-1beta or TARC. These results provide strong evidence that, at physiologically relevant concentrations, I-309 is the only known human ligand for CCR8. These data also provide a framework for suggesting minimum requirements for the assignment of chemokine receptor-ligand pairs.

摘要

趋化因子受体及其相关配体的鉴定对于理解大多数免疫反应至关重要。据报道,三种人类趋化因子[I-309、胸腺和活化调节趋化因子(TARC)以及巨噬细胞炎性蛋白-1β(MIP-1β)]是CC趋化因子受体8(CCR8)的配体。在本报告中,我们提供证据表明,TARC和MIP-1β在稳定转染细胞系(1D-21)上不与CCR8结合或通过CCR8诱导趋化作用,并且在体外分化的人CD4(+) Th(2)细胞培养物中不与CCR8结合。此外,I-309可使1D-21细胞和Th(2)细胞中依赖I-309的钙动员脱敏,但MIP-1β或TARC则不能。这些结果提供了强有力的证据,表明在生理相关浓度下,I-309是CCR8唯一已知的人类配体。这些数据还为提出趋化因子受体-配体对的分配最低要求提供了框架。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验